Skip to main content
China Resources Pharmaceutical Group Limited logo

China Resources Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 3320 ISIN · HK0000311099 LEI · 3003004H1KDKMJ8JD874 HKEX Manufacturing
Open in API
Filings indexed 813 across all filing types
Latest filing 2024-03-01 Regulatory Filings
Country HK Hong Kong
Listing HKEX 3320

About China Resources Pharmaceutical Group Limited

http://www.crpharm.com

China Resources Pharmaceutical Group Limited operates an integrated pharmaceutical value chain encompassing research and development, manufacturing, distribution, and retail of medicines and healthcare products. As an investment holding company, it manages a diverse portfolio focused primarily on the domestic market. Its manufacturing capabilities span multiple therapeutic areas, including chemical drugs, biological drugs, natural medicine, and traditional Chinese medicine. The group leverages its extensive distribution network and retail operations to ensure broad market coverage across China.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 29 February 2024. It details movements in issued shares, share options, and confirms no changes in authorized share capital or other share-related movements. The document is submitted to the Hong Kong Exchanges and Clearing Limited and includes specific stock code and share counts. It is a regulatory submission about share capital movements rather than a financial report, earnings release, or management discussion. It is not an announcement of a report publication but a regulatory filing required by the exchange rules. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is about 5,066 characters, consistent with a detailed regulatory filing rather than a brief announcement or a full annual/interim report.
2024-03-01 English
INSIDE INFORMATION THE PROPOSED INTERNAL REORGANIZATION INVOLVING CR ZIZHU
Regulatory Filings Classification · 95% confidence The document is an announcement by China Resources Pharmaceutical Group Limited regarding a proposed internal reorganization involving the transfer of shares between subsidiaries. It discusses the board resolution, the share transfer agreement, valuation by an independent valuer, and implications under the Listing Rules. The document is an announcement of a corporate restructuring transaction and does not contain financial statements or detailed financial performance data. It is not a full annual or interim report, nor is it a call transcript or earnings release. It is also not a proxy solicitation or voting result announcement. The document is a regulatory announcement about a significant corporate transaction (internal reorganization) and its compliance with listing rules. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories. The document length (7840 characters) and content confirm it is a detailed announcement rather than a brief notice or a report publication announcement.
2024-02-23 English
CONNECTED TRANSACTION ENTRUSTED CONSTRUCTION AGREEMENT WITH SHENZHEN RUNZHI
Regulatory Filings Classification · 95% confidence The document is an announcement by a Hong Kong listed company regarding a connected transaction involving an entrusted construction agreement with a related party. It details the terms, parties, scope, fees, and regulatory implications under the Listing Rules. The document is a formal announcement of a corporate transaction rather than a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis. It is not a report publication announcement since it contains substantive transaction details and regulatory disclosures. The content fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about a connected transaction under the Listing Rules, which is a common type of regulatory disclosure in Hong Kong markets.
2024-02-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 January 2024. It details movements in issued shares, share options, and confirms no changes in authorized share capital or other share-related movements. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting share capital and share option movements for a specific month. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to share capital movements and compliance with exchange listing rules. The document length is about 5,068 characters, which is substantive but the content is clearly a regulatory compliance report rather than a financial or management report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-02-01 English
ANNOUNCEMENT KEY OPERATING DATA OF JIANGZHONG PHARMACEUTICAL FOR THE YEAR 2023
Earnings Release Classification · 95% confidence The document is an announcement from China Resources Pharmaceutical Group Limited regarding the key operating data of Jiangzhong Pharmaceutical for the year 2023. It provides preliminary operating revenue and net profit estimates, explicitly stating that the data is unaudited and that the official annual report will be disclosed by Jiangzhong Pharmaceutical. The document is short (2981 characters) and serves as a preliminary results announcement rather than a full financial report. It does not contain detailed financial statements or comprehensive analysis, but rather a summary of estimated operating results. This fits the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. FY 2023
2024-01-29 English
ANNOUNCEMENT RESULTS ESTIMATE OF DONG-E-E-JIAO FOR THE YEAR ENDED 31 DECEMBER 2023
Earnings Release Classification · 90% confidence The document is an announcement of a results estimate for the year ended 31 December 2023 by Dong-E-E-Jiao, a subsidiary of the Company. It provides estimated net profit figures and earnings per share but explicitly states that the results estimate has not been audited or reviewed and that the detailed financial data will be disclosed in the annual report. The document is relatively short (5322 characters) and serves as a preliminary earnings estimate rather than a full financial report. It is not a full Annual Report (10-K) or Interim Report (IR), nor is it a full Earnings Release (ER) since it is an estimate and not final results. The document is an announcement of estimated financial results, which fits best under the Earnings Release (ER) category as it provides key highlights of financial performance for a period. Therefore, the appropriate classification is ER with high confidence. FY 2023
2024-01-26 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.